News

Euclid Vision Welcomes Specialty Eyecare Professional to Commercial Team

Euclid Vision Corp., a global leader in specialty contact lenses and proactive myopia management initiatives, is pleased to announce the continued expansion of its U.S. sales team with the addition of Jon R. Hudson, ABOC, NCLEC, who has joined the company as account executive for Texas, and Central and Southern U.S. territories. Jon brings 24 years of experience in the eye care industry to his new role.

“We are all very excited to have Jon join our commercial team. The addition of Jon to the U.S. sales force will enable Euclid and Visionary Optics to assist more eye care professionals (ECPs) in providing best-in-class services to more patients, and reinforces our commitment to ECPs and their patients,” said David Bland, Euclid Vision, vice president of sales.

Jon started his career in the eye care industry as a lab technician and optician in both retail and independent eye care practices and followed that by managing independent eye care practices prior to branching off on his own as a practice management consultant. His time with independent practices was focused primarily on maximizing per patient revenue, including the implementation of myopia management programs and initiatives designed to add scleral lenses as a treatment option. Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050. Jon’s passion for myopia management led to his employment with CooperVision Specialty EyeCare, where he held various roles over the course of six years. His primary focus involved development of practice management initiatives for myopia management and training the sales team on implementation of those programs.

Euclid Vision acquired Visionary Optics, a specialty scleral contact lens design and manufacturing pioneer, in 2022. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.  “As Euclid Vision and Visionary Optics focus on assisting more ECPs with their efforts to deliver best-in-class specialty contact lens services, in areas such as orthokeratology, scleral, and keratoconus management, Jon’s expansive experience in all sectors of eye care is the perfect fit for our commercial team and the customers we serve in this geographic region,” said Bland.

 

Learn more here.

Recent News

11/21/2025

A new era of global growth: George Mason and Naugen launch international innovation accelerator

This month, a new Northern Virginia International Soft-Landing Accelerator (NISA) program, designed to help start-ups from around the globe find guidance, connections, and lab or office spaces at no cost, was launched to help develop new technologies in life sciences.Applications are now open for the first NISA cohort. Participants in the six-month program will have

11/20/2025

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia’s life sciences ecosystem, higher-ed universities, and community colleges on October 31. This

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical